Changes in body mass index before and after starting dolutegravir and compared to protease inhibitors in children and adolescents living with HIV in Europe and Thailand
Viral suppression, viral failure and safety outcomes in children and adolescents ondolutegravir (DTG) in Europe and Thailand
New Action Plan to accelerate bNAbs for peri- and post-natal HIV prophylaxis released
It’s time for action: Protect children and pregnant people from Hepatitis
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium
Flexible Bayesian estimation of incubation times
Penta’s Young Reporters at the International Workshop on Pediatrics and HIV 2024
Viral failure in children and adolescents living with HIV on dolutegravir (DTG) in Europe and Thailand
Effectiveness and Safety of Dolutegravir in Children and Adolescents Living With HIV in Europe and Thailand
Learning from conect4children: A Collaborative Approach towards Standardisation of Disease-Specific Paediatric Research Data
PediCAP trial findings disseminated to Mozambican healthcare community
SUPPORT project launches to equip the next generation of African experts to fight childhood HIV
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years